Instituto RosenbuschBUE:ROSE 37 Current Ratio is 0.87 as of Dec. 2025, which is 50% below its 10-year median of 1.75. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS61.86 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 997 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 87.36% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Instituto Rosenbusch's current ratio for the quarter that ended in Dec. 2025 was 0.87.
Instituto Rosenbusch has a current ratio of 0.87. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Instituto Rosenbusch has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Instituto Rosenbusch's Current Ratio or its related term are showing as below:
BUE:ROSE'
s Current Ratio Range Over the Past 10 Years
Min: 0.87 Med: 1.75 Max: 2.1
Current: 0.87
During the past 13 years, Instituto Rosenbusch's highest Current Ratio was 2.10. The lowest was 0.87. And the median was 1.75.
BUE:ROSE's Current Ratio is ranked worse than 87.36% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs BUE:ROSE: 0.87
Instituto Rosenbusch (BUE:ROSE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Instituto Rosenbusch Current Ratio Related Terms
Instituto Rosenbusch Current Ratio Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Current Ratio distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a Current Ratio of 0.87 as of Dec. 2025. This is 50% below median its historical median of 1.75. Over the past decade, Instituto Rosenbusch's Current Ratio has ranged from 0.87 to 2.10. According to the industry distribution chart, Instituto Rosenbusch ranks #871 out of 997 companies in the Drug Manufacturers industry, placing it in the top 87.4%.
Is Instituto Rosenbusch's Current Ratio too high?
Instituto Rosenbusch's current Current Ratio of 0.87 is 50% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 2.10. The Drug Manufacturers industry median Current Ratio is 2.00. Instituto Rosenbusch's value of 0.87 is 56.5% below this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #871 out of 997 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #871 out of 997 companies for Current Ratio. This places Instituto Rosenbusch in the lower half of its industry. The industry median Current Ratio is 2.00. Instituto Rosenbusch's value of 0.87 is 56.5% below this benchmark. Historically, Instituto Rosenbusch's own Current Ratio has ranged from 0.87 to 2.10 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 2.00, Instituto Rosenbusch has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current Current Ratio of 0.87 is 56.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Current Ratio is 0.87, which is 50% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.86, compared to a current price of ARS163.00 — trading 163.5% above its estimated fair value. The current Current Ratio is 0.87, which is 50% below median its 10-year median of 1.75 and 56.5% below the Drug Manufacturers industry median of 2.00. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Current Ratio is 0.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS163.00 is trading 163.5% above its estimated GF Value™ of ARS61.86.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Current Ratio: 0.87 (50% below median its 10-year median of 1.75)
GF Value™: ARS61.86 vs. price of ARS163.00 (163.5% above fair value)
Industry Position: 56.5% below the Drug Manufacturers median (#871 of 997)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
